M0250 – Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose

Long description

Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose

Short description

Adm tocilizu covid-19 2nd

Pricing indicator

54 Vaccinations

Medicare coverage

C Carrier judgment – coverage decided by the Medicare contractor

BETOS category

O1G Immunizations/Vaccinations

Added

June 24, 2021

Last change

June 24, 2021 – No change

Nearby M codes

• M0241 – Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses
• M0243 – Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring
• M0244 – Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
• M0245 – Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring
• M0246 – Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency
• M0247 – Intravenous infusion, sotrovimab, includes infusion and post administration monitoring
• M0248 – Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
• M0249 – Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose
• M0300 – Iv chelation therapy (chemical endarterectomy)
• M0301 – Fabric wrapping of abdominal aneurysm
• M1000 – Pain screened as moderate to severe
• M1001 – Plan of care to address moderate to severe pain documented on or before the date of the second visit with a clinician
• M1002 – Plan of care for moderate to severe pain not documented on or before the date of the second visit with a clinician, reason not given
• M1003 – Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy
• M1004 – Documentation of medical reason for not screening for tb or interpreting results (i.e., patient positive for tb and documentation of past treatment; patient who has recently completed a course of anti-tb therapy)
• M1005 – Tb screening not performed or results not interpreted, reason not given